SIGA
SIGA Technologies, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$339M
5Y Perf.-21.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SIGA vs REGN
Revenue, margins, valuation, and 5-year total return — side by side.
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology
Market Cap$73.68B
5Y Perf.+15.7%
SIGA vs REGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SIGA | REGN |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $339M | $73.68B |
| Revenue (TTM) | $94M | $14.92B |
| Net Income (TTM) | $-4.04T | $4.42B |
| Gross Margin | 61.8% | 84.5% |
| Operating Margin | 27.7% | 24.3% |
| Forward P/E | 2.8x | 15.3x |
| Total Debt | $595K | $2.71B |
| Cash & Equiv. | $155M | $3.12B |
SIGA vs REGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SIGA
REGN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SIGA Technologies, … (SIGA) | 100 | 79.0 | -21.0% |
| Regeneron Pharmaceu… (REGN) | 100 | 115.7 | +15.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SIGA vs REGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REGN leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. SIGA Technologies, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
SIGA
SIGA Technologies, Inc.
The Income Pick
SIGA is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 4 yrs, beta 1.15, yield 12.7%
- 7.6% 10Y total return vs REGN's 90.0%
- Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
Best for: income & stability and long-term compounding
REGN
Regeneron Pharmaceuticals, Inc.
The Growth Play
REGN carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 1.0%, EPS growth 8.2%, 3Y rev CAGR 5.6%
- 1.0% revenue growth vs SIGA's -31.8%
- 29.6% margin vs SIGA's -43K%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | REGN | 1.0% revenue growth vs SIGA's -31.8% |
| Value | SIGA | Lower P/E (2.8x vs 15.3x) |
| Quality / Margins | REGN | 29.6% margin vs SIGA's -43K% |
| Stability / Safety | REGN | Beta 0.81 vs SIGA's 1.15 |
| Dividends | SIGA | 12.7% yield, 4-year raise streak, vs REGN's 0.5% |
| Momentum (1Y) | REGN | +27.1% vs SIGA's +1.5% |
| Efficiency (ROA) | REGN | 11.1% ROA vs SIGA's -7.4%, ROIC 8.9% vs 33.7% |
SIGA vs REGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
SIGA vs REGN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSIGALAGGINGREGN
REGNRegeneron Pharmaceuti…
2leads
SIGASIGA Technologies, In…
3leads
6 Total Categories
CATEGORYLEADERvs REGNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
REGN3/5
Valuation MetricsMultiples, price ratios, and targets
SIGA6/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SIGA4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
REGN2/2
Analyst OutlookRatings, price targets, and dividends
SIGA2/2
Income & Cash Flow (Last 12 Months)
REGN leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
REGN is the larger business by revenue, generating $14.9B annually — 159.1x SIGA's $94M. REGN is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, REGN holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SIGASIGA Technologies… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $94M | $14.9B |
| EBITDAEarnings before interest/tax | $26M | $4.2B |
| Net IncomeAfter-tax profit | -$4.04T | $4.4B |
| Free Cash FlowCash after capex | $33M | $4.2B |
| Gross MarginGross profit ÷ Revenue | +61.8% | +84.5% |
| Operating MarginEBIT ÷ Revenue | +27.7% | +24.3% |
| Net MarginNet income ÷ Revenue | -43117.4% | +29.6% |
| FCF MarginFCF ÷ Revenue | +35.2% | +27.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -11.3% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -7.2% |
REGN leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
SIGA leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 14.3x trailing earnings, SIGA trades at a 16% valuation discount to REGN's 17.1x P/E. On an enterprise value basis, SIGA's 7.6x EV/EBITDA is more attractive than REGN's 17.8x.
| Metric | SIGASIGA Technologies… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $339M | $73.7B |
| Enterprise ValueMkt cap + debt − cash | $185M | $73.3B |
| Trailing P/EPrice ÷ TTM EPS | 14.33x | 17.09x |
| Forward P/EPrice ÷ next-FY EPS est. | 2.78x | 15.35x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.70x |
| EV / EBITDAEnterprise value multiple | 7.60x | 17.78x |
| Price / SalesMarket cap ÷ Revenue | 3.58x | 5.14x |
| Price / BookPrice ÷ Book value/share | 1.70x | 2.46x |
| Price / FCFMarket cap ÷ FCF | 6.96x | 18.06x |
SIGA leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
SIGA leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
REGN delivers a 14.3% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-11 for SIGA. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to REGN's 0.09x.
| Metric | SIGASIGA Technologies… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -10.7% | +14.3% |
| ROA (TTM)Return on assets | -7.4% | +11.1% |
| ROICReturn on invested capital | +33.7% | +8.9% |
| ROCEReturn on capital employed | +11.3% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.00x | 0.09x |
| Net DebtTotal debt minus cash | -$154M | -$412M |
| Cash & Equiv.Liquid assets | $155M | $3.1B |
| Total DebtShort + long-term debt | $595,169 | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 108.44x |
SIGA leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — SIGA and REGN each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in REGN five years ago would be worth $14,365 today (with dividends reinvested), compared to $10,136 for SIGA. Over the past 12 months, REGN leads with a +27.1% total return vs SIGA's +1.5%. The 3-year compound annual growth rate (CAGR) favors SIGA at 6.9% vs REGN's -1.7% — a key indicator of consistent wealth creation.
| Metric | SIGASIGA Technologies… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | -15.0% | -8.5% |
| 1-Year ReturnPast 12 months | +1.5% | +27.1% |
| 3-Year ReturnCumulative with dividends | +22.2% | -5.1% |
| 5-Year ReturnCumulative with dividends | +1.4% | +43.6% |
| 10-Year ReturnCumulative with dividends | +764.0% | +90.0% |
| CAGR (3Y)Annualised 3-year return | +6.9% | -1.7% |
Evenly matched — SIGA and REGN each lead in 3 of 6 comparable metrics.
Risk & Volatility
REGN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
REGN is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than SIGA's 1.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 86.4% from its 52-week high vs SIGA's 49.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SIGASIGA Technologies… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.15x | 0.81x |
| 52-Week HighHighest price in past year | $9.62 | $821.11 |
| 52-Week LowLowest price in past year | $4.29 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +49.2% | +86.4% |
| RSI (14)Momentum oscillator 0–100 | 47.0 | 44.9 |
| Avg Volume (50D)Average daily shares traded | 688K | 631K |
REGN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
SIGA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates SIGA as "Buy" and REGN as "Buy". For income investors, SIGA offers the higher dividend yield at 12.73% vs REGN's 0.48%.
| Metric | SIGASIGA Technologies… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $865.68 |
| # AnalystsCovering analysts | 1 | 48 |
| Dividend YieldAnnual dividend ÷ price | +12.7% | +0.5% |
| Dividend StreakConsecutive years of raises | 4 | 1 |
| Dividend / ShareAnnual DPS | $0.60 | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.4% |
SIGA leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
SIGA leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). REGN leads in 2 (Income & Cash Flow, Risk & Volatility). 1 tied.
Best OverallSIGA Technologies, Inc. (SIGA)Leads 3 of 6 categories
Loading custom metrics...
SIGA vs REGN: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is SIGA or REGN a better buy right now?
For growth investors, Regeneron Pharmaceuticals, Inc.
(REGN) is the stronger pick with 1. 0% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). SIGA Technologies, Inc. (SIGA) offers the better valuation at 14. 3x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SIGA or REGN?
On trailing P/E, SIGA Technologies, Inc.
(SIGA) is the cheapest at 14. 3x versus Regeneron Pharmaceuticals, Inc. at 17. 1x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x.
03Which is the better long-term investment — SIGA or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc.
(REGN) delivered a total return of +43. 6%, compared to +1. 4% for SIGA Technologies, Inc. (SIGA). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus REGN's +90. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SIGA or REGN?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.
(REGN) is the lower-risk stock at 0. 81β versus SIGA Technologies, Inc. 's 1. 15β — meaning SIGA is approximately 43% more volatile than REGN relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SIGA or REGN?
By revenue growth (latest reported year), Regeneron Pharmaceuticals, Inc.
(REGN) is pulling ahead at 1. 0% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Regeneron Pharmaceuticals, Inc. grew EPS 8. 2% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SIGA or REGN?
Regeneron Pharmaceuticals, Inc.
(REGN) is the more profitable company, earning 31. 4% net margin versus 24. 6% for SIGA Technologies, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus 24. 9% for REGN. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SIGA or REGN more undervalued right now?
On forward earnings alone, SIGA Technologies, Inc.
(SIGA) trades at 2. 8x forward P/E versus 15. 3x for Regeneron Pharmaceuticals, Inc. — 12. 6x cheaper on a one-year earnings basis.
08Which pays a better dividend — SIGA or REGN?
All stocks in this comparison pay dividends.
SIGA Technologies, Inc. (SIGA) offers the highest yield at 12. 7%, versus 0. 5% for Regeneron Pharmaceuticals, Inc. (REGN).
09Is SIGA or REGN better for a retirement portfolio?
For long-horizon retirement investors, SIGA Technologies, Inc.
(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). Both have compounded well over 10 years (SIGA: +764. 0%, REGN: +90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SIGA and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
SIGA pays a dividend while REGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SIGA: -11.3% · REGN: 19.0%)P/E Ratio<
x
(SIGA: 14.3x · REGN: 17.1x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.